Abstract: The present invention relates to a stable parenteral composition comprising Cetrorelix or a pharmaceutically acceptable salt thereof, which is ready-to-use and does not require reconstitution prior to administration.

Abstract: The present disclosure provides a stable, ready-to-dilute injectable pharmaceutical composition comprising trabectedin and at least one pharmaceutically acceptable excipient, wherein the composition is free of ethanol.

Abstract: The present invention relates to a stable formulation of cyclophosphamide comprising a therapeutically effective amount of cyclophosphamide, ethanol as solvent, polyethylene glycol as the solvent, and optionally, monothioglycerol as the anti-oxidant, wherein the composition is stable over its shelf life.

Abstract: The present invention relates to a sterile, ready-to-use, aqueous composition of bortezomib that is stable over its shelf life.

Abstract: The present invention provides stable ready-to-use parenteral compositions of fosaprepitant and its pharmaceutically acceptable salts or derivatives. The compositions of the present invention do not require reconstitution and/or dilution prior to administration to the patient, and are stable over the shelf-life of the product.

Abstract: The present invention provides stable ready-to-use parenteral compositions of fosaprepitant and its pharmaceutically acceptable salts or derivatives. The compositions of the present invention do not require reconstitution and/or dilution prior to administration to the patient, and are stable over the shelf-life of the product.

Abstract: In some embodiments, the disclosure provides a method of making a sterile lacosamide composition, the method comprising; (a) obtaining a composition comprising (i) about 5 mg/mL to about 20 mg/mL lacosamide, (ii) about 5 mg/mL to about 12 mg/mL sodium chloride, and (iii) water, (b) placing the composition of (a) into a glass vial, wherein the glass vial has an ammonium sulfate coating, (c) sealing the composition inside the glass vial; and (d) autoclaving the sealed glass vial of (c) at 121° C. at 15 lbs pressure for 15 minutes, wherein the pH of the composition in (d) is substantially the same as the pH of the composition after (a), and wherein the composition of (d) comprises less than about 0.2% (wt/wt) of Impurity A, Impurity B, Impurity C, Impurity D, Impurity E or Impurity F.